Topic Review
Antibiotic Use and Resistance in Agriculture Sector
Possible new ways for the development of novel classes of antibiotics are discussed here, for which there is no pre-existing resistance in human bacterial pathogens. By utilizing research and technology such as nanotechnology and computational methods (such as in silico and Fragment-based drug design (FBDD)), there has been an improvement in antimicrobial actions and selectivity with target sites. Moreover, there are antibiotic alternatives, such as antimicrobial peptides, essential oils, anti-Quorum sensing agents, darobactins, vitamin B6, bacteriophages, odilorhabdins, 18β-glycyrrhetinic acid, and cannabinoids. Additionally, drug repurposing (such as with ticagrelor, mitomycin C, auranofin, pentamidine, and zidovudine) and synthesis of novel antibacterial agents (including lactones, piperidinol, sugar-based bactericides, isoxazole, carbazole, pyrimidine, and pyrazole derivatives) represent novel approaches to treating infectious diseases. Nonetheless, prodrugs (e.g., siderophores) have shown to be an excellent platform to design a new generation of antimicrobial agents with better efficacy against multidrug-resistant bacteria.
  • 328
  • 03 Apr 2023
Topic Review
Antibiotics in Avian Species
Bacterial infections are commonly diagnosed and treated with antibiotics in the avian species. Infected birds can spread zoonotic diseases such as influenza, psittacosis, pasteurellosis, and campylobacteriosis to humans, especially if they are in close contact with them, such as pet-owner settings, zoos, or pet shops. The elimination of bacterial infections in birds is therefore important for both human and avian health.
  • 1.1K
  • 08 Jun 2022
Topic Review
Antibody–Drug Conjugates for Non-Oncological Applications
Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. Inspired by these outcomes, scientists explored the potential of antibody–drug conjugates in non-oncological conditions such as arthritis, myasthenia gravis, immunological disorders, and kidney failure. 
  • 603
  • 07 Jul 2023
Topic Review
Anticancer Activity of Napabucasin
Napabucasin (also known as BBI608) is a natural naphthoquinone originally identified as a cancer cell stemness inhibitor. Accumulated in vitro and in vivo evidence demonstrated that napabucasin showed significant anticancer effects in various types of cancers. Napabucasin showed multiple anticancer activities, including proliferation inhibition, cell death induction, cell cycle arrest, metastasis suppression, drug resistance overcoming, and stemness inhibition, etc., which were documented in many benchworks.
  • 245
  • 09 Aug 2023
Topic Review
Anticancer Effects of α-Linolenic Acid
α-linolenic acid (ALA) belongs to the family of n-3 polyunsaturated fatty acids (n-3 PUFAs) and contains a carbon–carbon double bond on the third carbon atom at the methyl end of the carbon chain. This family of essential fatty acids also includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA has gradually attracted increased attention due to its nutritional and medicinal advantages. Studies have shown that ALA exerts beneficial effects on a variety of diseases, including cancer.
  • 102
  • 19 Mar 2024
Topic Review
Anticancer Nanotherapeutics in Clinical Trials
The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concepts of treatments based on physical treatments and biologics.
  • 619
  • 10 Nov 2022
Topic Review
Anticancer Potential of Piper nigrum
Current anticancer therapy suffers from several limitations, including lack of selectivity and multidrug resistance. Natural products represent an excellent opportunity for the identification of new therapeutic options due to their safety, low toxicity, and general availability. Piper nigrum is one of the most popular species in the world, with growing fame as a source of bioactive molecules with pharmacological properties. Undeniable anticancer properties are reportetd for different Piper nigrum constituents, such as its main alkaloid piperine.
  • 564
  • 27 Feb 2021
Topic Review
Anticancer Secondary Metabolites of Astragalus Species
Some of the most effective anticancer compounds are still derived from plants since the chemical synthesis of chiral molecules is not economically efficient. Rapid discovery of lead compounds with pronounced biological activity is essential for the successful development of novel drug candidates. The genus Astragalus L. is the largest in the family Fabaceae (syn. Leguminosae), with more than 3500 species. Astragalus, excluding Astracantha (formerly Astragalus subgenus Tragacantha), has a world total of ca. 2500 species, of which ca. 500 are in the Americas. Many of the species have conservation status “vulnerable” or “critically endangered”.
  • 564
  • 09 Sep 2022
Topic Review
Antidiabetic Properties of Plant Secondary Metabolites
Plants with a general tonic effect, plants containing insulin-like substances, plant purifiers, and plants rich in vitamins, organic acids, and other nutrients have been shown to play an important role in the treatment and prevention of type 2 diabetes mellitus and its complications.
  • 286
  • 19 Jun 2023
Topic Review
Antiepileptic Drugs
For drugs, such as antiepileptic drugs (AEDs), whose therapeutic or toxic effects are more closely related to blood levels than to a specific dose, monitoring of plasma levels plays a crucial role. Many drugs used in epilepsy therapy often cause acute poisonings (carbamazepine, oxcarbazepine, valproic acid, lamotrigine). AEDs do not have an ideal pharmacokinetic profile, which at the same time qualifies them to monitor both in the therapeutic and toxic aspects. Currently, a great benefit for patients using various AEDs is adjusting the dosage to their individual needs and monitoring sufficient blood concentrations. There is still a need to develop new, rapid methods that meet the validation criteria. This trend has been observed in the last few years in the bioanalysis of different type of biological samples, not only blood, serum or plasma, but also saliva and blood/serum/plasma dried spots technique.
  • 534
  • 01 Dec 2020
  • Page
  • of
  • 106
Video Production Service